Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW031 vs Prolia PK/PD Study in Healthy Adults
NCT04798313Phase 1Completed
- Sponsor
- Mabwell
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 9MW0311 in postmenopausal osteoporosis (2 arms), sponsored by Mabwell. Primary endpoints: Area under the plasma concentration-time curve (AUC0-t) and Maximum serum concentration. Started Jun 2020; status: completed.
02
Drugs
9MW0311
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04798313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798313.